Amritsar Online

Recurrent Glioblastoma Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – Apogenix, Tocagen, PharmAbcine, Celgene, DelMar Pharma, AbbVie, and Others

 Breaking News
  • No posts were found

Recurrent Glioblastoma Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – Apogenix, Tocagen, PharmAbcine, Celgene, DelMar Pharma, AbbVie, and Others

May 09
20:45 2022
Recurrent Glioblastoma Market to Accelerate Substantially During the Forecast Period - DelveInsight | Key Companies - Apogenix, Tocagen, PharmAbcine, Celgene, DelMar Pharma, AbbVie, and Others
Delveinsight Business Research LLP

DelveInsight’s “Recurrent Glioblastoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Recurrent Glioblastoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Recurrent Glioblastoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Recurrent Glioblastoma Market

Recurrent Glioblastoma: An Overview

According to the American Brain Tumor Association, Glioblastomas (also called GBM) are malignant Grade IV tumors, where a large portion of tumor cells reproduce and divide at any given time. The tumor is predominantly made up of abnormal astrocytic cells, which also contain a mixture of different cell types (including blood vessels) and areas of dead cells (necrosis). 

The mainstay of treatment for GBM is surgery, followed by radiation and chemotherapy. The primary objective of surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissue needed for normal neurological function (such as motor skills, the ability to speak and walk, etc.).

Recurrent glioblastoma is a possibility that oncologists and patients must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that cancer might come back after a period of remission. Glioblastoma can come back anywhere in the brain or spinal cord. However, most recurrences are found near the site of the original tumor.

Recurrent Glioblastoma Market Key Facts

  • The total incident population of GBM in the seven major markets was found to be 28,800+ in 2017, which is expected to increase by 2030. While the total diagnosed incident population of Recurrent GBM in the 7MM was 25,900+ in 2017.

  • Most incident cases of GBM were recorded in the United States, i.e., 13,600+ in 2017.

  • The incident population of GBM was found to be 2,500+ in 2017 in Japan.

  • Among the European 5 countries, the United Kingdom had the highest incident population of GBM, followed by France and Italy. On the other hand, Spain had the lowest incident population of GBM. 

Recurrent Glioblastoma Market

The patients with GBM continue to experience a tremendous burden of treatment, low survival rates, etc. Surgery proves to be a mainstay treatment for GBM but still remains understudied for recurrent GBM. There is a need for developing novel targeted therapies that shall fuel the market for Recurrent GBM.

As per DelveInsight, the Recurrent Glioblastoma market size is expected to increase during the forecast period owing to the rise in the number of incident cases in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Recurrent Glioblastoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Recurrent Glioblastoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Recurrent Glioblastoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Recurrent Glioblastoma Epidemiology Segmentation –

  • Total Diagnosed Incident Population of GBM

  • Total Diagnosed Recurrent Incident Population

  • Total Incident Population of GBM in the

  • Gender-specific Diagnosed Incidence of GBM

  • Type-specific Diagnosed Incidence of GBM

  • Incident Population of Associated Comorbidities in GBM

Recurrent Glioblastoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Glioblastoma market or expected to get launched during the study period. The analysis covers Recurrent Glioblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Recurrent Glioblastoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market

Recurrent Glioblastoma Therapeutics Analysis

The Recurrent GBM market dynamic is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise efficient treatment options.

The Recurrent GBM pipeline is robust and possesses multiple potential drugs in late and mid-stage Developments. The launch of emerging therapies is expected during the forecast period.

Some of the key companies in the Recurrent Glioblastoma Market include

  • Green Cross Cell Corporation

  • Celgene

  • DelMar Pharmaceuticals

  • VBL Therapeutics

  • AbbVie

  • Diffusion Pharmaceuticals

  • Johnpro Biotech

  • Bristol-Myers Squibb

  • Ono Pharmaceuticals

  • Apogenix

  • Tocagen

  • PharmAbcine

And many others. 

Recurrent Glioblastoma Therapies covered in the report include

  • Immuncell-LC

  • Marizomib

  • Dianhydrogalactitol (VAL-083)

  • Ofranergene obadenovec (VB-111)

  • Depatuxizumab mafodotin (ABT-414)

  • Trans Sodium Crocetinate

  • Siroquine (JP001)

  • Nivolumab

  • Ipilimumab

  • Asunercept

  • Toca 511 and Toca FC

  • TTAC-0001

And many more

Get More Detailed Insights Into the Emerging Therapies & Key Companies – 
https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Recurrent Glioblastoma Competitive Intelligence Analysis

4. Recurrent Glioblastoma Market Overview at a Glance

5. Recurrent Glioblastoma Disease Background and Overview

6. Recurrent Glioblastoma Patient Journey

7. Recurrent Glioblastoma Epidemiology and Patient Population

8. Recurrent Glioblastoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Recurrent Glioblastoma Unmet Needs

10. Key Endpoints of Recurrent Glioblastoma Treatment

11. Recurrent Glioblastoma Marketed Products

12. Recurrent Glioblastoma Emerging Therapies

13. Recurrent Glioblastoma Seven Major Market Analysis

14. Attribute Analysis

15. Recurrent Glioblastoma Market Outlook (7 major markets)

16. Recurrent Glioblastoma Access and Reimbursement Overview

17. KOL Views on the Recurrent Glioblastoma Market.

18. Recurrent Glioblastoma Market Drivers

19. Recurrent Glioblastoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Optic Neuropathy Market

DelveInsight’s “Optic Neuropathy Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Optic Neuropathy Market size, share, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles